Tata India Pharma & Healthcare IDCW Reinvest Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹5,000

Tata India Pharma & Healthcare IDCW Reinvest Direct Plan

NAV
₹33.9979
+0.42%
(22 Jan)
AUM
1,311 Cr
TER
0.62%
Risk
Very High Risk
Insights
Total Expense Ratio (TER) is in the bottom 25% of comparable funds
Net Asset Value (NAV) is below its 200 days moving average
In beta. Send feedback here.
Compare with other fund
1Y
+12.6%
+12.6%
+5.9%
+5.9%
-1.1%
3Y
+29.4%
+29.4%
+29.2%
+29.2%
+22.4%
5Y
+28.0%
+28.0%
+20.6%
+20.6%
+15.9%
ALL
+16.4%
+16.4%
+17.2%
+17.2%
+12.9%
VOL
20.1%
20.1%
17.8%
17.8%
15.4%
TER
0.9%
0.9%
0.5%
0.5%
0.6%
AUM
₹1,449 Cr
₹1,449 Cr
₹8,304 Cr
₹8,304 Cr
₹1,311 Cr
INFO
0.82
0.82
0.97
0.97
0.84
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Tata India Pharma & Healthcare IDCW Reinvest (DR)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Dec
Top holdings
Sun Pharmaceuticals Industries Ltd
7.9%
Max Healthcare Institute Ltd Ordinary Shares
5.9%
Abbott India Ltd
5.5%
Divi's Laboratories Ltd
5.0%
HealthCare Global Enterprises Ltd
4.8%
Apollo Hospitals Enterprise Ltd
4.8%
Cipla Ltd
4.1%
Rainbow Childrens Medicare Ltd
3.8%
Ipca Laboratories Ltd
3.7%
J.B. Chemicals & Pharmaceuticals Ltd
3.5%
Top industry exposure
Healthcare
95.0%
Basic Materials
3.7%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹5,000
Additional lumpsum
₹1,000
Portfolio turnover
78%
Lock-in period
-
Exit load
• 0.25% for redemption within 30 days
Fund objective
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Fund manager(s)
Rajat Srivastava

FAQs